FILI-PHARMA
ActiveFILI-PHARMA has been active since 2010 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €968k and a net result of €141k. Equity is growing by ~13.1% per year across the filed fiscal years. Its solvency ranks better than 83% of 907 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.6% (low).
Checked score
Score 2025
93
/ 100
Excellent= vs 2024
The score combines four axes. Every signal that weighs is under Signals.
Axes · tick = 2024
Profitability73▼-27
Solvency91▼-3
Growth78=
Stability100
Bankruptcy probability, 12 months
0.6%
Low
0%0.5%1.5%4%10%≥ 25%
Credit up to €90k at 30 days acceptable
Liquidity ample (current ratio 1.59 against 1.73 in 2024), and 22% of the assets are financed with debt.
Credit advice for your own amount and term
Signals
Six signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
raises risk · Higher-failure-rate sector
In this sector companies fail more often than the Belgian average.
Gazette · bankruptcies per sector, NACE 77
Relative position
BE, all sectors
reference
Sector 77
higher
← fewer bankruptcies
more bankruptcies →
lowers risk · Annual accounts: healthy financial profile
The latest annual accounts show a healthy profile in solvency, result and liquidity.
NBB · annual accounts 2025Solvency, return and age of the figures
Solvency
78%
Return on assets
11.4%
Age of the figures
14 mo
lowers risk · Long track record
A company with a long track record statistically fails less often than a young one.
KBO · incorporation dateAge against the risk zone
neutral · Latest accounts filed on time
The financial year that closed on 30-06-2025 was due by 31-01-2026 and was filed on 29-01-2026, 2 days ahead of the deadline.
NBB · 10 filingsDeviation from the deadline
2025
2 d early
2024
4 d early
2023
1 d early
2022
1 d early
2021
3 d early
2020
2 d early
2019
on the day
← before the deadline
after the deadline →
neutral · The next deadline is still running
The next financial year closes on 30-06-2026 and is due by 31-01-2027. Nothing is late today.
Companies Code · seven monthsPosition in the running window
30-06-2026 close14-09-2026 today31-01-2027 deadline
Financials · fiscal year 2025, abbreviated schema
Equity
€968k▲ 17.0%
2024 · €827k
2019: €446k
2020: €489k
2021: €531k
2022: €597k
2023: €659k
2024: €827k
2019 → 2025
Total assets
€1.24M▲ 11.1%
2024 · €1.12M
2019: €687k
2020: €715k
2021: €767k
2022: €848k
2023: €920k
2024: €1.12M
2019 → 2025
Net result
€141k▼ 16.3%
2024 · €168k
2019: €38k
2020: €43k
2021: €42k
2022: €66k
2023: €62k
2024: €168k
2019 → 2025
Working capital
€162k▼ 23.5%
2024 · €212k
2019: €-169k
2020: €-126k
2021: €-84k
2022: €-18k
2023: €44k
2024: €212k
2019 → 2025
Multi-year overview
Every figure with its change against the year before
▲ rise
▼ fall
Line20212022202320242025Trend
Equity€531k-€597k▲ 12.4%€659k▲ 10.4%€827k▲ 25.6%€968k▲ 17.0%
Operating result€63k-€100k▲ 57.5%€99k▼ 1.3%€100k▲ 1.7%€84k▼ 16.3%
Net result€42k-€66k▲ 54.9%€62k▼ 5.5%€168k▲ 171%€141k▼ 16.3%
Turnover and EBIT margin not published: the abbreviated schema does not require them.
Result per fiscal year
Operating resultNet result
The operating result falls in 2025; 2025 is 16% below 2024.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €1.24M
Fixed assets
€806k▲ 31.0%
Current assets
€436k▼ 13.2%
Equity and liabilities €1.24M
Equity
€968k▲ 17.0%
Debt
€273k▼ 5.7%
The debt ratio falls from 25.9% to 22.0%: equity grows while debt is paid down.
Key figures and ratios
EBITDA
€101k
Cash flow
€158k
Solvency
78.0%▲
2024 · 74.1%
Current ratio
1.59▼
2024 · 1.73
Quick ratio
1.59▼
2024 · 1.73
Debt / equity
0.28▼
2024 · 0.35
ROE
14.6%▼
2024 · 20.4%
ROA
11.4%▼
2024 · 15.1%
Interest coverage
5.96
Debt
€273k▼
2024 · €290k
Debt ≤ 1 year
€273k▼
2024 · €290k
Income taxes
€29k▼
2024 · €34k
Green means a favourable move, even when the figure itself falls: as with debt or debt / equity.
Filed annual accounts
As filed with the NBB · 2025 against 2024
Balance sheet
Code20242025
Assets
Total assets20/58€1.12M€1.24M▲
Fixed assets21/28€615k€806k▲
Tangible fixed assets22/27-€191k
Land and buildings22-€191k
Financial fixed assets28€615k€615k=
Current assets29/58€502k€436k▼
Amounts receivable within one year40/41€77k€96k▲
Trade receivables40€57k€80k▲
Other amounts receivable41€20k€16k▼
Cash at bank and in hand54/58€425k€340k▼
Deferred charges and accrued income490/1€20€21▲
Equity and liabilities
Total equity and liabilities10/49€1.12M€1.24M▲
Equity10/15€827k€968k▲
Contributions10/11€50k€50k=
Reserves13€571k€712k▲
Distributable reserves133€571k€712k▲
Profit (loss) carried forward14€206k€206k=
Amounts payable17/49€290k€273k▼
Amounts payable within one year42/48€290k€273k▼
Trade debts44€49-
Suppliers440/4€49-
Taxes, remuneration and social security45€45k€24k▼
Taxes450/3€43k€24k▼
Remuneration and social security454/9€2k-
Other amounts payable47/48€245k€249k▲
Income statement
Code20242025
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630-€17k
Other operating charges640/8€1k€1k▲
Gross operating margin9900€101k€103k▲
Operating profit (loss)9901€100k€84k▼
Financial income75/76B€120k€103k▼
Recurring financial income75€120k€103k▼
Financial charges65/66B€18k€17k▼
Recurring financial charges65€18k€17k▼
Profit (loss) for the period before taxes9903€202k€169k▼
Income taxes67/77€34k€29k▼
Profit (loss) for the period9904€168k€141k▼
Profit (loss) for the period to be appropriated9905€168k€141k▼
Appropriation of the result
Profit (loss) to be appropriated9906€374k€347k▼
Profit (loss) brought forward from the previous period14P€206k€206k=
Transfer to equity691/2€168k€141k▼
To other reserves6921€168k€141k▼
The notes to these accounts (6 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.
Timeline · acts, filings and financial milestones
Next filing, fiscal year 2026, expected by
2026
29-01
NBB filing
Annual accounts filed
fiscal year 2025 · abbreviated schema
2025
27-01
NBB filing
Annual accounts filed
fiscal year 2024 · abbreviated schema
2024
30-06
Financial
Highest result since 2019net €168k ▲171%
Operating result €100k, net result €168k, both a record.
30-01
NBB filing
Annual accounts filed
fiscal year 2023 · abbreviated schema
2023
30-01
NBB filing
Annual accounts filed
fiscal year 2022 · abbreviated schema
2022
28-01
NBB filing
Annual accounts filed
fiscal year 2021 · abbreviated schema
2021
30-06
Financial
Equity above €500kEq €531k ▲8.7%
3 profitable years in a row build equity to €531k.
29-01
NBB filing
Annual accounts filed
fiscal year 2020 · abbreviated schema
2020
31-01
NBB filing
Annual accounts filed
fiscal year 2019 · abbreviated schema
2019
31-01
NBB filing
Annual accounts filed
fiscal year 2018 · abbreviated schema
2018
31-01
NBB filing
Annual accounts filed
fiscal year 2017 · abbreviated schema
2017
31-01
NBB filing
Annual accounts filed
fiscal year 2016 · abbreviated schema
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
Directors · office · real estate
Directors
2 acts for this company are in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.
Location & real-estate footprint
Registered office, Ninove · 1 establishment unit since 2010
Cannot be placed on the map
This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.
Smid Lambrechtstraat 709406 NinoveGround area
503 m²
Building footprint
184 m²
Volume, LiDAR
1,188 m³
Parcel 41055A1080/00C000, Flanders · tallest building 10.3 m, ±2 floors. Linked by address, not a title deed.
1 establishment unit
FILI-PHARMA
since 20102.185.308.446
1 parcel
Flanders
1
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 41055A1080/00C000 | Flanders | 503 m² | 1 · 184 m² | 10.3 m · 2 fl. |
Linked by address, not proof of ownership
Methodology
via registered seat: 1
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Similar companies · same sector, comparable size
Althea Belgique
BE 0865.296.220
Grâce-Hollogne · Eq €962k
LABAB
BE 0422.213.581
Charleroi · Eq €901k
CENTRALE DE SERVICES A DOMICILE EN LUXEMBOURG
BE 0435.399.643
Saint-Hubert · Eq €811k
Aide á Domicile - Thuishulp
BE 0443.360.076
Brussel · Eq €794k
Solidarité Confort
BE 0548.646.648
Ans · Eq €755k
Of 142 companies in sector 77225 we hold annual accounts for 79. 48 are within a factor 10 of this equity.See the whole sector
Company data · Crossroads Bank
Identification
Legal formPrivate limited company
Founded27-01-2010
Fiscal year end30-06
Activities, NACEBEL
77225Rental and leasing activities
21100Manufacture of basic pharmaceutical products and pharmaceutical preparations
21209Manufacture of basic pharmaceutical products and pharmaceutical preparations
46450Wholesale of perfume and cosmetics
46460Wholesale of pharmaceutical and medical goods
47730Retail sale of pharmaceutical products
Sources
Crossroads Bank for EnterprisesNational Bank · 15 filingsAddress and cadastre registers
Data from official sources, last processed on 14-09-2026. Scores and ratios are computed by Checked and are not a credit decision.